An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer.

[1]  F. Saad,et al.  Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. , 2016, The Lancet. Oncology.

[2]  G. Scagliotti,et al.  Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. , 2016, Cancer treatment reviews.

[3]  A. Liede,et al.  Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction , 2015, Clinical epidemiology.

[4]  F. Saad,et al.  Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. , 2015, European urology.

[5]  I. Tannock,et al.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Neetu Chawla,et al.  Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. , 2014, Annals of epidemiology.

[7]  C. Jung,et al.  Experiences on conversion to once-daily Advagraf and sirolimus combination in stable kidney recipients. , 2014, Transplantation proceedings.

[8]  Eberechukwu Onukwugha,et al.  Concordance between administrative claims and registry data for identifying metastasis to the bone: an exploratory analysis in prostate cancer , 2014, BMC Medical Research Methodology.

[9]  C. Kyriakopoulos,et al.  Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison , 2014, Clinical Medicine Insights. Oncology.

[10]  Lois Lamerato,et al.  Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems , 2013, Supportive Care in Cancer.

[11]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[12]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[13]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[14]  M. Pino,et al.  A Changing Landscape in Castration-Resistant Prostate Cancer Treatment , 2012, Front. Endocrin..

[15]  M L Kilgore,et al.  Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006 , 2011, Prostate Cancer and Prostatic Diseases.

[16]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[17]  K. Tomer,et al.  Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. , 2011, Cancer research.

[18]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[19]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[20]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[21]  M. Shulman,et al.  The natural history of androgen independent prostate cancer. , 2004, The Journal of urology.

[22]  H. Moch,et al.  Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. , 2000, Human pathology.

[23]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[24]  W. Lowrance,et al.  Castration-resistant prostate cancer: AUA guideline amendment. , 2015, The Journal of urology.

[25]  M. Nørgaard,et al.  Clinical Epidemiology Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article , 2022 .